This series of bite-sized episodes will take you through the latest information regarding disrupted nighttime sleep and its relationship to cardiovascular risk, plus patient/clinician preferences regarding the treatment of narcolepsy with sodium oxybates.
The Etiology of CV Issues in Patients with Narcolepsy
The Etiology of CV Issues in Patients with Narcolepsy
Welcome to CME on ReachMD. This episode is part of our MinuteCME curriculum.
Prior to beginning the activity, please be sure to review the faculty and commercial support disclosure statements as well as the learning objectives.
This is CME on ReachMD, and I’m Dr. Michael Thorpy. Here with me today is Dr. Clete Kushida. Clete can you tell us a little bit about why patients with narcolepsy tend to have an increased cardiovascular risk? And what should we do about it once we know that they have this increased risk?
Mainly there’s two factors that have been clearly associated with the higher risk of individuals that have narcolepsy in developing cardiovascular disease. One of them is the sleep fragmentation, and the sleep fragmentation that’s associated with narcolepsy, as well as other sleep disorders such as obstructive sleep apnea and periodic limb movement disorder, can be associated with atherosclerosis. When they’ve studied mice that are subject to sleep fragmentation, it can produce things like more monocytes and also larger atherosclerotic lesions and also result in less hypocretin, and the decrease in hypocretin is the second factor. It can also lead to accelerated atherosclerosis. So, the sleep fragmentation plus the lowered hypocretin are definitely associated factors for the risk of myocardial infarction as well as obesity and accelerated atherosclerosis. Now, additionally, sleep fragmentation has also been associated with the development of congestive heart failure.
One of the positive aspects about the treatment of narcolepsy is drugs can improve the sleep fragmentation. So, they can improve the disrupted nocturnal sleep, particularly those related to sodium oxybate.
Well, thank you for that, Clete. So, disrupted sleep is an important part of narcolepsy and can contribute to the cardiovascular risk in these patients. And can you tell us a little bit more about how we would go about dealing with that issue of disrupted sleep in our patients?
Thanks, Michael. So a new product that’s been FDA approved is once-nightly sodium oxybate, and that allows less disruption of sleep because a patient with narcolepsy doesn’t have to awaken themselves in the middle of the night to take a second dose of sodium oxybate. So, the once-nightly oxybate the patient would take it at the beginning of the night, and that should allow more continuous sleep and preservation of their natural sleep-wake cycle resulting in less disruption of the night, and in doing so will reduce the association of narcolepsy with cardiovascular disease particularly with the relationship of the sleep fragmentation with elements like accelerated atherosclerosis.
Good. Well, thank you for that, Clete. There are a number of factors that contribute to this cardiovascular issues in these patients with narcolepsy, and you’ve mentioned some of the comorbidities that are important in that – the sleep apnea, the obesity – and also mentioned about the hypocretin loss. But one of the areas that a lot of people don’t realize is that it’s the disrupted sleep at night which is a major factor in contributing to cardiovascular risk in patients with narcolepsy, and as you mentioned, we now have medications that can improve nocturnal sleep, in particular, oxybate, which is really the only medication that is FDA approved for dealing with nighttime sleep in patients who have narcolepsy, and this can help reduce the disrupted sleep at night, which, again, will reduce the cardiovascular risk in our patients with narcolepsy. So, it’s really important when we look at the treatment of narcolepsy to consider all these factors and consider the medications that we have available because, you know, we also know that many of the alerting and weight promoting medications tend to exacerbate cardiovascular risk, whereas a medication such as oxybate, which improves nocturnal sleep, may not have those adverse effects on cardiovascular risk.
Well, this was a brief but great discussion. Unfortunately, our time is up, but thank you for listening.
You have been listening to CME on ReachMD. This activity is provided by Prova Education and is part of our MinuteCME curriculum.
To receive your free CME credit, or to download this activity, go to ReachMD.com/Prova. Thank you for listening.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Michael J. Thorpy, MD
Director, Sleep‐Wake Disorders Center
Montefiore Medical Center
Professor of Neurology, Albert Einstein College of Medicine
Consulting/Advisory Board: Alkermes, Avadel Pharmaceuticals, Axsome, Balance Therapeutics, Eisai Pharmaceuticals, Harmony Biosciences, LLC, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, NLS Pharmaceuticals, Suven Life Sciences Ltd., Takeda Pharmaceutical Co., Ltd, XW Pharma
Clete A. Kushida, MD, PhD
Professor, Division Chief
Medical Director, Sleep Medicine
Stanford University School of Medicine
Consulting Fees: XW Pharma
Research: Avadel Pharmaceuticals
Ann Marie Morse, DO
Director, Child Neurology and Pediatric Sleep Medicine
Geisinger Medical Center
Janet Weis Children’s Hospital
Consulting Fees: Alkermes, Avadel Pharmaceuticals, Jazz Pharmaceuticals, Harm Reduction Therapeutics, Takeda Pharmaceutical Co.
Research: Geisinger Health Plan, Jazz Pharmaceuticals, NIH, UCB,
Other: Damm Good Sleep, LLC
Franz H. Messerli, MD
Professor of Medicine
University of Bern
No relevant relationships reported.
- Jennifer Brutsche has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Elizabeth Lurwick has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Robert Schneider, MSW, has nothing to disclose.
- Peer Review, if applicable, Brian P. McDonough, MD, FAAFP, has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Evaluate the efficacy and safety of available sodium oxybate therapies in improving outcomes for patients with narcolepsy
- Describe the quality-of-life impact and potential cardiovascular effects of disrupted nighttime sleep on patients with narcolepsy
- Compare and contrast various federal and medical society guidelines, as well as clinical trial data, as to what constitutes appropriate sodium intake
- Define the counseling processes by which patients and clinicians can communicate about goals of treatment and implement shared decision-making as to the therapeutic management approach
This activity is designed to meet the educational needs of sleep medicine specialists, psychiatrists, and neurologists.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Avadel Pharmaceuticals.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.